| Identification | Back Directory | [Name]
Glycine, N-[[5-(3-fluorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]- | [CAS]
1007377-55-0 | [Synonyms]
AKB6899
AKB-6899
AKB 6899
Glycine, N-[[5-(3-fluorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-
antiangiogenic,Inhibitor,AKB 6899,antitumor,AKB-6899,HIF-PH,HIF-2α,sVEGFR-1,HIF/HIF Prolyl-Hydroxylase,HIFs,inhibit,Hypoxia-inducible factors,PHD3 | [Molecular Formula]
C14H11FN2O4 | [MDL Number]
MFCD32204728 | [MOL File]
1007377-55-0.mol | [Molecular Weight]
290.25 |
| Chemical Properties | Back Directory | [Boiling point ]
653.5±55.0 °C(Predicted) | [density ]
1.436±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
4.09±0.40(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1]. | [in vivo]
AKB-6899 (17.5 mg/kg; i.p.; 3 times per week; for 16 days) treatment significantly reduces tumor growth in a murine melanoma model[1]. | Animal Model: | 6-8-week-old C57BL/6 mice injected with B16F10 murine melanoma cells[1] | | Dosage: | 17.5 mg/kg | | Administration: | i.p.; 3 times per week; for 16 days | | Result: | Significantly reduced tumor growth. |
| [storage]
Store at -20°C | [References]
[1] Julie M Roda, et al. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012 Sep 15;189(6):3168-77. DOI:10.4049/jimmunol.1103817 |
|
|